News und Analysen
![GenSight Biologics Announces Update on Real-World Data from Early Access Programs of LUMEVOQ® Gene Therapy at NANOS 2024: https://mms.businesswire.com/media/20240305810568/en/2056132/5/Figure_1_-_BCVA_EAP_-_ENG.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNE5MYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--77e0535b1c7734d98697358a06ae7427847c3c1c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Figure_1_-_BCVA_EAP_-_ENG.jpg?locale=de)
GenSight Biologics Announces Update on Real-World Data from Early Access Programs of LUMEVOQ® Gene Therapy at NANOS 2024
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240305810568/en/
(Graphic: Business Wire)
GenSight Biologics
![GenSight Biologics Announces Presentation of LUMEVOQ® Efficacy and Safety Data from Early Access Programs for ND4-LHON Patients at NANOS 2023: https://mms.businesswire.com/media/20230314006021/en/1738792/5/5008596cGraph_EAP_en.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK2ZVYWc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--d8f83e909d63b4d37fbe51df137e6c52fd74deee/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/5008596cGraph_EAP_en.jpg?locale=de)
GenSight Biologics Announces Presentation of LUMEVOQ® Efficacy and Safety Data from Early Access Programs for ND4-LHON Patients at NANOS 2023
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230314006021/en/
Figure 1: Global evolution of mean BCVA over two
![GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections at 3-Year Follow-Up of REFLECT Phase III Trial: https://mms.businesswire.com/media/20230312005028/en/1736264/5/Graph_REFLECT.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN3JSYWc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--74ba79f2db671d412cb94e1b222c1f7c98e857e1/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Graph_REFLECT.jpg?locale=de)
GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections at 3-Year Follow-Up of REFLECT Phase III Trial
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230312005028/en/
Graph 1: Evolution of Best-Corrected Visual Acuity
![GenSight Biologics Announces Publication of Indirect Comparison of LUMEVOQ® Versus Natural History in ND4-LHON Patients in Peer-Reviewed Journal Ophthalmology and Therapy: https://mms.businesswire.com/media/20221214006010/en/1665781/5/4847924cFigure1_en_%281%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBek9TV1E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--af1cc37e5826e3f2685612b6547a1c0d9a342354/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/4847924cFigure1_en_-281-29.jpg?locale=de)
GenSight Biologics Announces Publication of Indirect Comparison of LUMEVOQ® Versus Natural History in ND4-LHON Patients in Peer-Reviewed Journal Ophthalmology and Therapy
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221214006010/en/
Figure 1: from Indirect Comparison of Lenadogene
Form 8.3 - The Vanguard Group, Inc.: Sanofi
Form 8.3 - The Vanguard Group, Inc.: Sanofi
Form 8.3 - The Vanguard Group, Inc.: Sanofi
![GenSight Biologics reports 5 years’ data showing sustained efficacy and safety following one-time treatment with LUMEVOQ®: https://mms.businesswire.com/media/20220719006077/en/1518423/5/Gensight.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMWZSV0E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--01e2c6f0397025240400d66fbebd032eccfe1cee/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Gensight.jpg?locale=de)
GenSight Biologics reports 5 years’ data showing sustained efficacy and safety following one-time treatment with LUMEVOQ®
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220719006077/en/
Figure 1. Evolution of BCVA In LUMEVOQ®-treated
![Transgene’s Board of Directors Strengthens Its Governance and Proposes the Appointment of Dr. Alessandro Riva as Independent Chairman](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Transgene’s Board of Directors Strengthens Its Governance and Proposes the Appointment of Dr. Alessandro Riva as Independent Chairman
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220331005765/en/
Dr. Alessandro Riva (Photo: Transgene)
Transgene
![GenSight Biologics Reports Clinically Meaningful Vision Improvement is Maintained 4 Years After One-time Treatment with LUMEVOQ® Gene Therapy](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
GenSight Biologics Reports Clinically Meaningful Vision Improvement is Maintained 4 Years After One-time Treatment with LUMEVOQ® Gene Therapy
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220123005091/en/
Figure 1. Evolution of BCVA In LUMEVOQ®-treated
![GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections at 2-Year Follow-Up of REFLECT Phase III Trial](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections at 2-Year Follow-Up of REFLECT Phase III Trial
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211213005948/en/
Figure 1. Best-Corrected Visual Acuity (BCVA) Change
![Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
![Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech
![Mauna Kea Technologies Unveils CellTolerance, a Subsidiary Dedicated to its Unique Program for the Detection and Treatment of Food Intolerances: https://mms.businesswire.com/media/20240626399128/en/337855/5/mkt_logo_bg_1024-300dpi.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBekhFYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3f16fce5b447747b8a7f3fe8cab92cedd6ff35e6/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/mkt_logo_bg_1024-300dpi.jpg?locale=de)
Mauna Kea Technologies Unveils CellTolerance, a Subsidiary Dedicated to its Unique Program for the Detection and Treatment of Food Intolerances
Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary platform for probe-based and needle-based confocal laser endomicroscopy (p/nCLE)
![GenSight Biologics Renegotiates Financial Obligations and Provides Operational Updates: https://mms.businesswire.com/media/20191208005050/en/761225/5/Logo+Centre+Hospitalier+XV-XX.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMXBqRmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--32e5498581c41f5af17897302b60481289223182/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Logo+Centre+Hospitalier+XV-XX.jpg?locale=de)
GenSight Biologics Renegotiates Financial Obligations and Provides Operational Updates
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
![ABIONYX Pharma has completed a successful pre-IND meeting with the FDA for CER-001 Phase 2b/3 Clinical Trial for Patients with Sepsis: https://mms.businesswire.com/media/20210302005302/en/862456/5/ABIONYX_W.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM0FtVmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3f52df4b7747dcabeb26ea260ead9545699cca5c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/ABIONYX_W.jpg?locale=de)
ABIONYX Pharma has completed a successful pre-IND meeting with the FDA for CER-001 Phase 2b/3 Clinical Trial for Patients with Sepsis
ABIONYX Pharma, (FR0012616852 - ABNX - eligible for PEA PME), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural
![Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
![GenSight Biologics to Present at Upcoming Medical Conferences and Stakeholder Meetings: https://mms.businesswire.com/media/20191208005050/en/761225/5/Logo+Centre+Hospitalier+XV-XX.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMXBqRmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--32e5498581c41f5af17897302b60481289223182/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Logo+Centre+Hospitalier+XV-XX.jpg?locale=de)
GenSight Biologics to Present at Upcoming Medical Conferences and Stakeholder Meetings
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
![GenSight Biologics Appoints William Monteith to its Board of Directors: https://mms.businesswire.com/media/20191208005050/en/761225/5/Logo+Centre+Hospitalier+XV-XX.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMXBqRmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--32e5498581c41f5af17897302b60481289223182/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Logo+Centre+Hospitalier+XV-XX.jpg?locale=de)
GenSight Biologics Appoints William Monteith to its Board of Directors
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (Paris:SIGHT), a biopharma company focused on developing and commercializing innovative gene therapies
![Sartorius Stedim Biotech Capital Markets: Links to presentation and webcast](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Sartorius Stedim Biotech Capital Markets: Links to presentation and webcast
![Poxel Reports Revenue for the First Quarter 2024 and Provides Corporate Update: https://mms.businesswire.com/media/20210929005940/en/578635/5/POXEL_LOGO_Q.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOTA1Vnc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a443757a54f31cbfc57d9b7b8b30d0d59fbe9bd4/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/POXEL_LOGO_Q.jpg?locale=de)
Poxel Reports Revenue for the First Quarter 2024 and Provides Corporate Update
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
![Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024
![Abivax annual ordinary and extraordinary general meeting of May 30, 2024 - Availability of the preparatory documents](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Abivax annual ordinary and extraordinary general meeting of May 30, 2024 - Availability of the preparatory documents
![GenSight Biologics: Annual General Meeting on May 29, 2024: https://mms.businesswire.com/media/20191208005050/en/761225/5/Logo+Centre+Hospitalier+XV-XX.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMXBqRmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--32e5498581c41f5af17897302b60481289223182/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Logo+Centre+Hospitalier+XV-XX.jpg?locale=de)
GenSight Biologics: Annual General Meeting on May 29, 2024
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
![Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)